Absolutely. You can see the caveats that BioHorizons put in place to protect itself with OCC if a takeover occurs. Its almost comedic how obvious US pharma' interest is in this company, but the share price languishes still. We should get the qtrly report this evening, which should hopefully give a little more insight into the operational progress on the quarter with BH.
I was very pleasantly surprised when OCC announced the Striate deal with BH. I will not be surprised when it goes on a trading halt to announce another deal/partnership in any of the potentially more lucrative aspects of its CelGro/ATI/ACI bio-technologies.
Ann: Investor Presentation, page-16
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.45M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 37.0¢ | $34.15K | 92.31K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14000 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 20208 | 2 |
View Market Depth
| Last trade - 10.07am 10/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |